PHAS
PhaseBio Pharmaceuticals, Inc. Common Stock
PHAS
PHAS
Delisted
PHAS was delisted on the 2nd of November, 2022.
49 hedge funds and large institutions have $14M invested in PhaseBio Pharmaceuticals, Inc. Common Stock in 2022 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 12 increasing their positions, 13 reducing their positions, and 13 closing their positions.
New
Increased
Maintained
Reduced
Closed
less repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
less funds holding
Funds holding: →
less first-time investments, than exits
New positions opened: | Existing positions closed:
less capital invested
Capital invested by funds: $ → $
Holders
49
Holding in Top 10
–
Calls
–
Puts
–
Top Buyers
| 1 | +$450K | |
| 2 | +$174K | |
| 3 | +$96.6K | |
| 4 |
Stifel Financial
St. Louis,
Missouri
|
+$88.5K |
| 5 |
Jane Street
New York
|
+$68K |
Top Sellers
| 1 | -$3.76M | |
| 2 | -$2.21M | |
| 3 | -$1.39M | |
| 4 |
VPW
Vericrest Private Wealth
Newtown,
Pennsylvania
|
-$1.39M |
| 5 |
ECM
Endurant Capital Management
San Mateo,
California
|
-$322K |